Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

Gerd R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Philip J Mease, Emma Guttman‑Yassky

10.1136/rmdopen-2022-002735

February 8, 2023

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial

Huijing Wang, Ting Li, Fangfang Sun, Zhe Liu, Danting Zhang, Xiangyu Teng, Laurence Morel, Xiaodong Wang, Shuang Ye

10.1136/rmdopen-2022-002686

October 26, 2022

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

Jeffrey I Weitz, Zoltán Szekanecz, Christina Charles-Schoeman, Ivana Vranic, Burak Sahin, Sara A Paciga, Zhenyu Wang, Craig Hyde, David A Martin

10.1136/rmdopen-2022-002571

November 2, 2022

Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial

Victoria Navarro-Compán, James Cheng-Chung Wei, Filip Van den Bosch, Marina Magrey, Lisy Wang, Dona Fleishaker, Joseph C Cappelleri, Cunshan Wang, Joseph Wu, Oluwaseyi Dina, Lara Fallon, Vibeke Strand

10.1136/rmdopen-2022-002253

June 2, 2022

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

Dinesh Khanna, Toby M Maher, Elizabeth R Volkmann, Yannick Allanore, Vanessa Smith, Shervin Assassi, Michael Kreuter, Anna-Maria Hoffmann-Vold, Masataka Kuwana, Christian Stock, Margarida Alves, Steven Sambevski, Christopher P Denton

10.1136/rmdopen-2022-002859

February 16, 2023

Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study

Xiaomei Leng, Wei Lin, Shixue Liu, Keith Kanik, Cunshan Wang, Weiguo Wan, Zhenyu Jiang, Yi Liu, Shengyun Liu, Zhuoli Zhang, Zhiyi Zhang, Jian Xu, Wenfeng Tan, Jiankang Hu, Jingyang Li, Ju Liu, Levent M. Gunay, Oluwaseyi Dina, Cassandra Kinch, Xiaofeng Zeng

10.1136/rmdopen-2022-002559

January 31, 2023

Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations

George C Drosos, George Konstantonis, Petros P Sfikakis, Maria G Tektonidou

10.1136/rmdopen-2022-002767

February 9, 2023

Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs

James M Gwinnutt, Maud Wieczorek, Javier Rodríguez-Carrio, Andra Balanescu, Heike A Bischoff-Ferrari, Annelies Boonen, Giulio Cavalli, Savia de Souza, Annette de Thurah, Thomas E Dorner, Rikke Helene Moe, Polina Putrik, Lucía Silva-Fernández, Tanja Stamm, Karen Walker-Bone, Joep Welling, Mirjana Zlatković-Švenda, Francis Guillemin, Suzanne M M Verstappen

10.1136/rmdopen-2021-002167

June 2, 2022

Antibodies against citrullinated proteins of IgA isotype are associated with progression to rheumatoid arthritis in individuals at-risk

Maria V Sokolova, Fabian Hartmann, Daniela Sieghart, Holger Bang, Guenter Steiner, Arnd Kleyer, Georg Schett, Ulrike Steffen

10.1136/rmdopen-2022-002705

January 30, 2023

Interstitial lung disease in rheumatoid arthritis: incidence, prevalence and related drug prescriptions between 2007 and 2020

Katinka Albrecht, Anja Strangfeld, Ursula Marschall, Johanna Callhoff

10.1136/rmdopen-2022-002777

January 20, 2023

Most Read Articles